Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

4SC Discovery Receives Research Grant of EUR 600,000

Published: Monday, February 11, 2013
Last Updated: Monday, February 11, 2013
Bookmark and Share
Munich m4 biotech cluster programme supports research collaboration with the Medical Clinic of the University of Munich on preclinical development of novel compounds for cancer immunotherapy.

4SC AG has announced that its subsidiary 4SC Discovery GmbH, which specializes in the discovery and early-stage research of new compounds, is to receive a research grant of approximately EUR 600,000 for the development of new cancer drugs in the area of personalized medicine.

As part of the Munich-based leading-edge biotech cluster programme m4, the grant will support a research collaboration between 4SC Discovery and the project group for Immune Pharmacology (Dr. Sebastian Kobold) in the department of Clinical Pharmacology headed by Professor Dr. Stefan Endres from the Medical Clinic of the Ludwig-Maximilians University of Munich.

The aim of this collaboration is to advance the preclinical development of so-called TLR7 and TLR8 agonists for use in cancer immunotherapy.

The project is intended to promote the further development of substances which influence the immune system of cancer patients in such a way that the immune system recognizes the cancer cells and destroys them.

Given that the ability of the immune system to react to abnormal cells depends significantly on the immune status and immune competence of the patient, personalized medicine pursues a therapeutic approach which involves a simultaneous biomarker analysis of the particular patients.

The collaboration starts in November 2012 and is scheduled to run for a period of two years.

Dr. Daniel Vitt, Managing Director of 4SC Discovery GmbH and Chief Scientific Officer of 4SC AG, said: 'Alongside epigenetics and cancer stem cells, cancer immunotherapy is definitely one of the most exciting and dynamic areas of current cancer research. 4SC has been researching this field for years now and we are delighted to receive funding from the Munich biotech cluster of excellence, m4, to further intensify this research. Our objective in this subsidized collaboration with Professor Endres from the Medical Clinic of the University of Munich is to perform preclinical tests on our compounds and optimize them so that we can begin the clinical development of the compounds in patients soon.'

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Developing Drug Resistance may be a Matter of Diversity for Tuberculosis
Researchers have probed the bacteria that causes tuberculosis, Mycobacterium tuberculosis, to learn more about how individual bacterial cells change and adapt while in the human body.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
Essential Component of Antiviral Defense Identified
Infectious disease researchers at the University of Georgia have identified a signaling protein critical for host defense against influenza infection.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Mucus – the First Line of Defence
Researchers reveal the important role of mucus in building a good defence against invaders.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Gene-Edited Immune Cells Treat ‘Incurable’ Leukaemia
A new treatment that uses ‘molecular scissors’ to edit genes and create designer immune cells programmed to hunt out and kill drug resistant leukaemia has been used at Great Ormond Street Hospital (GOSH).

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos